X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ASTRAZENECA PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ASTRAZENECA PHARMA PFIZER/
ASTRAZENECA PHARMA
 
P/E (TTM) x 31.2 104.6 29.9% View Chart
P/BV x 5.0 14.9 33.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 PFIZER   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
ASTRAZENECA PHARMA
Mar-14
PFIZER/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7241,285 212.0%   
Low Rs1,611634 254.1%   
Sales per share (Unadj.) Rs440.9189.6 232.5%  
Earnings per share (Unadj.) Rs48.7-0.2 -23,916.7%  
Cash flow per share (Unadj.) Rs75.83.8 1,970.9%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs462.968.6 674.5%  
Shares outstanding (eoy) m45.7525.00 183.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.95.1 97.1%   
Avg P/E ratio x44.5-4,712.7 -0.9%  
P/CF ratio (eoy) x28.6249.6 11.5%  
Price / Book Value ratio x4.714.0 33.5%  
Dividend payout %30.80-   
Avg Mkt Cap Rs m99,16323,988 413.4%   
No. of employees `0002.91.6 185.3%   
Total wages/salary Rs m2,7581,605 171.8%   
Avg. sales/employee Rs Th6,981.73,040.2 229.6%   
Avg. wages/employee Rs Th954.51,029.2 92.7%   
Avg. net profit/employee Rs Th771.1-3.3 -23,618.4%   
INCOME DATA
Net Sales Rs m20,1704,740 425.6%  
Other income Rs m85792 930.9%   
Total revenues Rs m21,0284,832 435.2%   
Gross profit Rs m4,310-130 -3,320.3%  
Depreciation Rs m1,239101 1,224.0%   
Interest Rs m50-   
Profit before tax Rs m3,923-139 -2,824.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m99139 71.2%   
Tax Rs m1,7945 35,253.4%   
Profit after tax Rs m2,228-5 -43,767.6%  
Gross profit margin %21.4-2.7 -780.2%  
Effective tax rate %45.7-3.7 -1,248.1%   
Net profit margin %11.0-0.1 -10,284.8%  
BALANCE SHEET DATA
Current assets Rs m16,2992,726 597.8%   
Current liabilities Rs m7,5942,435 311.9%   
Net working cap to sales %43.26.1 702.0%  
Current ratio x2.11.1 191.7%  
Inventory Days Days6574 88.5%  
Debtors Days Days2641 63.2%  
Net fixed assets Rs m8,6221,035 832.8%   
Share capital Rs m45850 915.0%   
"Free" reserves Rs m20,722942 2,198.9%   
Net worth Rs m21,1801,716 1,234.3%   
Long term debt Rs m250-   
Total assets Rs m29,1374,156 701.1%  
Interest coverage x755.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.1 60.7%   
Return on assets %7.7-0.1 -6,257.4%  
Return on equity %10.5-0.3 -3,546.1%  
Return on capital %19.00-  
Exports to sales %0.15.7 1.0%   
Imports to sales %17.56.5 270.5%   
Exports (fob) Rs m12270 4.4%   
Imports (cif) Rs m3,526306 1,151.1%   
Fx inflow Rs m52375 13.8%   
Fx outflow Rs m140470 29.8%   
Net fx Rs m-88-96 92.4%   
CASH FLOW
From Operations Rs m3,436-8 -42,423.5%  
From Investments Rs m-6,991-146 4,798.1%  
From Financial Activity Rs m-619862 -71.8%  
Net Cashflow Rs m-4,174709 -589.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 0.3 2,500.0%  
FIIs % 4.9 15.7 31.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 9.1 260.4%  
Shareholders   85,207 12,856 662.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 23, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS